Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-182"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-182"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Providing patients with better access to quality information about the treatment being administered to them increases the chances of them understanding the decision directly affecting them. There is therefore a very good intention behind this; however, it must be part of a more comprehensive health education strategy, which focuses on the patient and not on the pharmaceutical company. There are many problems with the current legal framework and the situation within Europe when it comes to patients’ access to information about prescription-only medicines. The differences in interpretations of the directive by Member States give patients in different parts of Europe different access to high quality information on the relevant drugs. In some Member States it is difficult to access even the most basic information about the drugs which are prescribed. This creates health inequalities. Patients have unlimited access via the Internet to uncontrolled and frequently incorrect information about prescription-only medicines in a few seconds. However, they need to have access to controlled, safe information so as not to complicate matters even more. Therefore, the provisions regarding information about prescribed drugs need to be updated."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples